Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks
Its been shown to help repair ulcers, reduce inflammation, and protect the gut lining in models of colitis and leaky gut
As your order volume increases, the cost per unit decreases, allowing for more efficient budget allocation for your laboratory operations
No tirzepatide is contraindicated in individuals with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Its important to watch closely and teach patients about these risks
US$ 20.98
US$ 28.38
US$ 26.49
US$ 20.54
US$ 24.79
US$ 23.00
US$ 24.90
US$ 21.18
